Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Mexico | Healthcare | Pharmaceuticals | MX$15.12T | 70.8x | 0.72 | MX$17,017 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J&J | Mexico | Healthcare | Pharmaceuticals | MX$8.22T | 28.7x | -0.49 | MX$3,417 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Mexico | Healthcare | Pharmaceuticals | MX$7.80T | 90.2x | -7.36 | MX$4,431.50 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk | Mexico | Healthcare | Pharmaceuticals | MX$7.19T | 24.1x | 1.22 | MX$1,600 | -9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Mexico | Healthcare | Pharmaceuticals | MX$5.69T | 31.1x | -1.05 | MX$7,169.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | Mexico | Healthcare | Pharmaceuticals | MX$4.91T | 14.1x | 0 | MX$1,945 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca DRC | Mexico | Healthcare | Pharmaceuticals | MX$4.82T | 33.7x | 1.88 | MX$1,528 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Mexico | Healthcare | Pharmaceuticals | MX$4.58T | 19.4x | -1.08 | MX$2,027 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Mexico | Healthcare | Pharmaceuticals | MX$3.58T | 43x | -1.08 | MX$6,665 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Mexico | Healthcare | Pharmaceuticals | MX$3.07T | 18.8x | 0.07 | MX$542.66 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Mexico | Healthcare | Pharmaceuticals | MX$3.02T | 24.7x | 8.51 | MX$1,197 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Mexico | Healthcare | Pharmaceuticals | MX$2.98T | 305x | -3.28 | MX$2,347 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb | Mexico | Healthcare | Pharmaceuticals | MX$2.61T | -14.2x | 0.06 | MX$1,261 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Mexico | Healthcare | Pharmaceuticals | MX$1.67T | 24.6x | -0.51 | MX$767 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | Mexico | Healthcare | Pharmaceuticals | MX$1.63T | 29.6x | -22.68 | MX$11,995.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Mexico | Healthcare | Pharmaceuticals | MX$500.67B | -8.9x | -0.71 | MX$435.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva DRC | Mexico | Healthcare | Pharmaceuticals | MX$357.59B | -10.1x | 0.06 | MX$309.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | Mexico | Healthcare | Pharmaceuticals | MX$140.21B | 45x | 0.17 | MX$126.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bausch Health | Mexico | Healthcare | Pharmaceuticals | MX$53.24B | -57.6x | -0.61 | MX$151 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genomma Lab Int | Mexico | Healthcare | Pharmaceuticals | MX$21.60B | 10.9x | 0.12 | MX$23.35 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ |